Trial Profile
A phase 2, double-blind, dose-finding, placebo-controlled study to assess the safety and efficacy of a single oral administration of OBE001 to improve embryo implantation following IVF or ICSI
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Nolasiban (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Acronyms IMPLANT; IMPLANT-1
- Sponsors ObsEva
- 04 Aug 2021 According to an ObsEva media release, results of meta-analysis of three studies (IMPLANT, IMPLANT2 & IMPLANT 4) assessing pregnancy rate in the nolasiban 900 mg vs placebo groups, published in the Journal of Human Reproduction.
- 04 Aug 2021 Results published in an ObsEva Media Release.
- 30 Jun 2021 Results presented in an ObsEva media release.